SCHEMBL6973742

SCHEMBL6973742

COc1ccc(NS(=O)(=O)c2ccc(Cl)cc2)cc1N1CCNCC1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 20/20 0.80
HTR1A P08908 3/20 0.66
HTR2C P28335 3/20 0.66
HTR7 P34969 3/20 0.66
DRD2 P14416 2/20 0.66
HTR1D P28221 2/20 0.66
HTR1B P28222 2/20 0.66
ADRA1B P35368 2/20 0.66
DRD3 P35462 2/20 0.66
HTR4 Q13639 2/20 0.66
DRD1 P21728 1/20 0.66
DRD4 P21917 1/20 0.66
HTR2A P28223 1/20 0.66
HTR2B P41595 2/20 0.65
CYP1A2 P05177 1/20 0.65
ADRB1 P08588 1/20 0.65
CYP3A4 P08684 1/20 0.65
ADRA2A P08913 1/20 0.65
CYP2D6 P10635 1/20 0.65
ADRB3 P13945 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6975332 0.91 HTR6 (0.80) HTR6HTR1AHTR2CHTR7DRD2
SCHEMBL6976495 0.89 HTR6 (0.92) HTR6HTR1AHTR2CHTR7HTR2B
SCHEMBL6980079 0.89 HTR6 (0.80) HTR6HTR1AHTR2CHTR7DRD2
SCHEMBL6979261 0.89 HTR6 (1.00) HTR6HTR1AHTR2CHTR7DRD2
SCHEMBL6979091 0.88 HTR6 (0.79) HTR6HTR1AHTR2CHTR7HTR2B
SCHEMBL6980929 0.88 HTR6 (0.85) HTR6HTR1AHTR2CHTR7DRD2
SCHEMBL6972493 0.88 HTR6 (0.83) HTR6HTR1AHTR2CHTR7DRD2
SCHEMBL6978439 0.87 HTR6 (0.77) HTR6HTR1AHTR2CHTR7DRD2
SCHEMBL6187705 0.87 HTR6 (1.00) HTR6HTR1AHTR2CHTR7HTR2B
SCHEMBL6186144 0.87 HTR6 (1.00) HTR6HTR1AHTR2CHTR7HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0946539-B1 SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 2003-08-13 EP claimed
US-20030069233-A1 Sulphonamide derivatives, process for their preparation, and their use as medicaments SMITHKLINE BEECHAM P.L.C. 2003-04-10 US claimed
CN-1246116-A Sulfonamide derivatives, process for their preparation and their use as medicaments SMITHKLINE BEECHAM PLC (GB) 2000-03-01 CN claimed
EP-0946539-A1 SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 1999-10-06 EP claimed
WO-1998027081-A1 SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 1998-06-25 WO claimed
EP-0946539-B1 SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 2003-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069233-A1 Sulphonamide derivatives, process for their preparation, and their use as medicaments TPMT, MPST, STS HTR6 1537/4885HTR1A 2960/4885HTR2C 3448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.